Candriam Luxembourg S.C.A. Purchases 13,000 Shares of The Medicines Company (MDCO)
Candriam Luxembourg S.C.A. boosted its position in The Medicines Company (NASDAQ:MDCO) by 16.9% during the second quarter, Holdings Channel reports. The firm owned 90,000 shares of the company’s stock after buying an additional 13,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in The Medicines were worth $3,421,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Aviva Holdings Ltd. purchased a new position in The Medicines during the first quarter worth $187,477,000. Iridian Asset Management LLC CT increased its position in The Medicines by 218.7% in the first quarter. Iridian Asset Management LLC CT now owns 3,022,681 shares of the company’s stock worth $147,809,000 after buying an additional 2,074,261 shares during the period. Blue Ridge Capital L.L.C. purchased a new position in The Medicines during the first quarter worth $53,790,000. Frontier Capital Management Co. LLC increased its position in The Medicines by 139.9% in the first quarter. Frontier Capital Management Co. LLC now owns 604,020 shares of the company’s stock worth $29,537,000 after buying an additional 352,230 shares during the period. Finally, Vanguard Group Inc. increased its position in The Medicines by 5.4% in the first quarter. Vanguard Group Inc. now owns 6,090,730 shares of the company’s stock worth $297,837,000 after buying an additional 313,876 shares during the period.
Shares of The Medicines Company (NASDAQ MDCO) opened at 36.29 on Wednesday. The stock has a 50 day moving average price of $38.15 and a 200 day moving average price of $44.46. The firm’s market cap is $2.58 billion. The Medicines Company has a 12-month low of $30.80 and a 12-month high of $55.95.
MDCO has been the subject of a number of recent research reports. ValuEngine downgraded The Medicines from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 20th. Cowen and Company upped their price target on The Medicines from $39.00 to $61.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 19th. Oppenheimer Holdings, Inc. initiated coverage on The Medicines in a research report on Monday, May 22nd. They set a “market perform” rating and a $50.00 price target for the company. CIBC set a $50.00 price target on The Medicines in a research report on Tuesday, May 23rd. Finally, Citigroup Inc. reduced their price target on The Medicines from $59.00 to $43.00 and set a “neutral” rating for the company in a research report on Monday, July 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $53.73.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Want to see what other hedge funds are holding MDCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Medicines Company (NASDAQ:MDCO).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.